Compare TFIN & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFIN | SRPT |
|---|---|---|
| Founded | 1981 | 1980 |
| Country | United States | United States |
| Employees | 1450 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | N/A | 2000 |
| Metric | TFIN | SRPT |
|---|---|---|
| Price | $79.79 | $17.22 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 29 |
| Target Price | ★ $66.20 | $25.85 |
| AVG Volume (30 Days) | 253.0K | ★ 3.6M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | $7.27 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $66.31 | ★ $6.01 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $46.43 | $10.42 |
| 52 Week High | $80.57 | $25.32 |
| Indicator | TFIN | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 63.96 | 45.16 |
| Support Level | $60.93 | $15.55 |
| Resistance Level | $80.47 | $18.16 |
| Average True Range (ATR) | 2.56 | 1.07 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 93.70 | 19.78 |
Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.